# Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC

> **NCT05941338** · PHASE2 · RECRUITING · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 100 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma
- Oral Cancer

## Interventions

- **DRUG:** Tirelizumab ,+Carboplatin+albumin-bound paclitaxel

## Key facts

- **NCT ID:** NCT05941338
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-01
- **Primary completion:** 2025-02-28
- **Final completion:** 2030-02-28
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05941338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05941338, "Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05941338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*